Distractions Not Associated with Working Memory Impairment in Schizophrenia
the Psychiatry Advisor take:
Cognitive impairment is readily seen in patients with schizophrenia due to deficits in what is known as working memory (WM) capacity. Although this has been known for some time, the exact cause of WM deficit remains poorly understood.
Researchers at the Maryland Psychiatric Research Center at the University of Maryland School of Medicine, led by Molly A. Erickson, looked at whether selection attention impairments contributed to capacity development. They used experimental paradigm that assesses the role of selective attention in WM encoding and has been shown to involve the prefrontal cortex and the basal ganglia.
In the first experiment, participants were required to remember the locations of three or five target items (red circles). In another, three target items were accompanied by two distractor items (yellow circles), which participants were instructed to ignore.
People who had schizophrenia showed impairment in being able to locate the target items, though both those with and without schizophrenia showed no difference in their ability to filter the distractors, according to data published in Schizophrenia Bulletin. The same was seen in the second experiment.
“Taken together, these results demonstrate that reduced WM capacity in [people with schizophrenia] is not attributable to a failure of filtering irrelevant distractors,” the researchers concluded.
Distractions Do Not Contribute to Memory Impairment in Those With Schizophrenia
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Predictors of Long-term Medication Adherence in Children With ADHD
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- SSRI Dose Increase Not Recommended for Antidepressant Treatment Failure
- Perimenstrual Symptom Exacerbation Observed in Borderline Personality Disorder
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Good Sleep Tied to Better Cardiometabolic Health in Youths
- Public Support Only Moderate for Opioid Harm Reduction Strategies